Synaptogenix Announces Conference Call to Discuss AAIC Abstract Findings
Synaptogenix, Inc. (Nasdaq: SNPX) announced a conference call on July 26, 2021, to discuss findings from its abstract presented at the Alzheimer's Association International Conference. The call will feature CEO Dr. Alan Tuchman and President Dr. Daniel Alkon, who will address live Q&A. Synaptogenix is focused on therapies for neurodegenerative diseases, primarily through its lead candidate, Bryostatin-1, which has shown promise in Alzheimer's and Fragile X syndrome. The FDA has granted Orphan Drug Designation for Bryostatin-1 in treating Fragile X syndrome.
- Synaptogenix is developing Bryostatin-1, showing potential in treating Alzheimer’s and Fragile X syndrome.
- The FDA has granted Orphan Drug Designation to Bryostatin-1 for Fragile X syndrome, validating its clinical significance.
- The success of Bryostatin-1 is uncertain, with risks related to safety, efficacy, and regulatory approval.
- The company faces challenges such as financing issues, long drug development timelines, and competition.
NEW YORK, July 21, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that it will hold a conference call for investors to discuss its abstract presented at the Alzheimer's Association International Conference. The call will take place on Monday, July 26th at 4:15pm ET and will be hosted by the Company's Chief Executive Officer, Dr. Alan Tuchman, and its President and Chief Science Officer, Dr. Daniel Alkon. Drs. Tuchman and Alkon will take live Q&A following their prepared remarks.
The U.S. toll free dial-in for the conference call is (877) 407-9205, and the international dial-in number is 1-(201)-689-8054. A live webcast of the conference call will also be available via: https://www.webcaster4.com/Webcast/Page/2599/42216.
About Synaptogenix, Inc.
Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Preclinical studies have also demonstrated Bryostatin's regenerative mechanisms of action for the rare disease, Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs.
Additional information about Synaptogenix, Inc. may be found on its website: www.synaptogen.com.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding the Phase 2 clinical trial of Bryostatin-1 and further studies, and continued development of use of Bryostatin-1 for AD and other cognitive diseases. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. There can be no assurance that the clinical program for Bryostatin-1 will be successful in demonstrating safety and/or efficacy, that we will not encounter problems or delays in clinical development, or that Bryostatin-1 will ever receive regulatory approval or be successfully commercialized. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Additional factors that may influence or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company's patent portfolio, the Company's inability to expand its business, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, availability of the Company's raw materials, existing or increased competition, stock volatility and illiquidity, and the Company's failure to implement its business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the Securities and Exchange Commission. The Company does not undertake to update these forward-looking statements.
Contact information:
Investors and Media
Investor Relations
Brett Maas
Hayden IR
brett@haydenir.com
(646)536-7331
Robert Weinstein
Chief Financial Officer
Synaptogenix, Inc.
rweinstein@synaptogen.com
View original content:https://www.prnewswire.com/news-releases/synaptogenix-announces-conference-call-to-discuss-aaic-abstract-findings-301338270.html
SOURCE Synaptogenix, Inc.
FAQ
What is the purpose of Synaptogenix's conference call on July 26, 2021?
Who will lead the conference call for Synaptogenix?
What is Bryostatin-1 and its significance?
Has Bryostatin-1 received any designations from the FDA?
What risks are associated with Synaptogenix's drug development?
